{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:16:10Z","timestamp":1785820570722,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.leukres.2019.106287","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T16:41:50Z","timestamp":1575996110000},"page":"106287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates \u2013 A multicenter cohort study"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-3181","authenticated-orcid":false,"given":"Wellington F. da","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Manoel Marques","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiane In\u00eas da","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Bellesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Villa","family":"Cl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia Torresan","family":"Delamain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2019.106287_bib0005","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.106287_bib0010","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncr.21562","article-title":"Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy","volume":"106","author":"Diamond","year":"2006","journal-title":"Cancer."},{"key":"10.1016\/j.leukres.2019.106287_bib0015","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.clml.2014.06.020","article-title":"HIV-related hematological malignancies: a concise review","volume":"14","author":"Rios","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2013","key":"10.1016\/j.leukres.2019.106287_bib0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation-2013.1.382","article-title":"Update on the treatment of HIV-associated hematologic malignancies","author":"Little","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2019.106287_bib0025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2019.106287_bib0030","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","article-title":"How I treat Burkitt lymphoma in adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2019.106287_bib0035","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-intensive chemotherapy including rituximab in Burkitt\u2019s leukemia or lymphoma regardless of human immunodeficiency virus infection status","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer."},{"key":"10.1016\/j.leukres.2019.106287_bib0040","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2017.180893","article-title":"Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study","volume":"103","author":"Schommers","year":"2018","journal-title":"Haematologica."},{"key":"10.1016\/j.leukres.2019.106287_bib0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1120009X.2018.1535771","article-title":"Treatment outcomes of adult Burkitt lymphoma: results with a modified LMB protocol in Brazil and feasibility of outpatient administration","volume":"30","author":"da Silva Junior","year":"2018","journal-title":"J. Chemother."},{"key":"10.1016\/j.leukres.2019.106287_bib0050","doi-asserted-by":"crossref","first-page":"s4","DOI":"10.1590\/S0102-311X2011001300001","article-title":"The HIV\/AIDS epidemic in Brazil: three decades","volume":"27","author":"Szwarcwald","year":"2011","journal-title":"Cad. Saude Publica"},{"key":"10.1016\/j.leukres.2019.106287_bib0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.leukres.2019.106287_bib0060","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition)","year":"2017"},{"key":"10.1016\/j.leukres.2019.106287_bib0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt leukemia and lymphoma","author":"Blum","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2019.106287_bib0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106287_bib0075","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin Lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106287_bib0080","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer."},{"key":"10.1016\/j.leukres.2019.106287_bib0085","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin\u2019s Lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106287_bib0090","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/cncr.11628","article-title":"Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma","volume":"98","author":"Wang","year":"2003","journal-title":"Cancer."},{"key":"10.1016\/j.leukres.2019.106287_bib0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1750-9378-10-4","article-title":"HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts","volume":"10","author":"Castilho","year":"2015","journal-title":"Infect. Agent. Cancer."},{"key":"10.1016\/j.leukres.2019.106287_bib0100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6061\/clinics\/2014(05)12","article-title":"Time-to-treatment of diffuse large B-cell lymphoma in S\u00e3o Paulo","volume":"69","author":"Xavier","year":"2014","journal-title":"Clinics."},{"key":"10.1016\/j.leukres.2019.106287_bib0105","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000000623","article-title":"Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy","volume":"29","author":"Alwan","year":"2015","journal-title":"AIDS."},{"issue":"2012","key":"10.1016\/j.leukres.2019.106287_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/735392","article-title":"HIV-associated burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M\/IVAC with or without rituximab in the HAART era","author":"Rodrigo","year":"2012","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.leukres.2019.106287_bib0115","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia","volume":"94","author":"Cortes","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2019.106287_bib0120","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with burkitt\u2019s lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.106287_bib0125","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology","volume":"101","author":"Little","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2019.106287_bib0130","first-page":"188","article-title":"Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R","volume":"130","author":"Roschewski","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2019.106287_bib0135","series-title":"Rituximab Does Not Improve Clinical Outcome in a Randomized Phase 3 Trial of CHOP With or Without Rituximab in Patients With HIV-associated Non-hodgkin Lymphoma: AIDS-Malignancies Consortium Trial 010","author":"Kaplan","year":"2005"},{"key":"10.1016\/j.leukres.2019.106287_bib0140","unstructured":"S.K. Barta, X. Xue, D. Wang, R. Tamari, J.Y. Lee, N. Mounier, L.D. Kaplan, J.-M. Ribera, M. Spina, U. Tirelli, R. Weiss, L. Galicier, F. Boue, W.H. Wilson, C. Wyen, A. Oriol, J. Jos\u00b4, J.-T. Tom\u00b4, T. Navarro, K. Dunleavy, R.F. Little, L. Ratner, O. Garcia, M. Morgades, S.C. Remick, A. Noy, J.A. Sparano, Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients Key Points, (n.d.). doi:10.1182\/blood-2013-04."},{"key":"10.1016\/j.leukres.2019.106287_bib0145","article-title":"Relapsed\/refractory burkitt lymphoma and HIV infection","author":"Khan","year":"2017","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.leukres.2019.106287_bib0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1377\/hlthaff.28.4.1103","article-title":"AIDS treatment in Brazil: impacts and challenges","volume":"28","author":"Nunn","year":"2009","journal-title":"Health Aff."},{"key":"10.1016\/j.leukres.2019.106287_bib0155","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1200\/JGO.2015.002378","article-title":"Burkitt\u2019s lymphoma and B-Cell lymphoma unclassifiable with features intermediate between diffuse large B-Cell lymphoma and burkitt\u2019s lymphoma in patients with HIV: outcomes in a south african public hospital","volume":"3","author":"Sissolak","year":"2017","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.leukres.2019.106287_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.03.001","article-title":"Treating adult acute lymphoblastic leukemia in Brazil\u2014increased early mortality using a german multicenter acute lymphoblastic leukemia-based regimen","volume":"18","author":"Fernandes da Silva Junior","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2019.106287_bib0165","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/sj.leu.2404785","article-title":"Treatment outcome and prognostic factors in an Indian population using a modified German ALL (GMALL) protocol","volume":"21","author":"Bajel","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.leukres.2019.106287_bib0170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2018-04-844472","article-title":"How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa","volume":"132","author":"Gopal","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2019.106287_bib0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High\u2010dose chemotherapy and immunotherapy in adult Burkitt lymphoma","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer."},{"key":"10.1016\/j.leukres.2019.106287_bib0180","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/QAD.0b013e3283301578","article-title":"Excellent immunological recovery following CODOX-M\/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt\u02bcs lymphoma","volume":"24","author":"Montoto","year":"2010","journal-title":"AIDS."},{"key":"10.1016\/j.leukres.2019.106287_bib0185","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/jjco\/hyu012","article-title":"Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan","volume":"44","author":"Kojima","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106287_bib0190","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjh.13221","article-title":"Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort","volume":"168","author":"Schommers","year":"2015","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:45Z","timestamp":1758934785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619307325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":38,"alternative-id":["S0145212619307325"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106287","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates \u2013 A multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106287"}}